Cover Image

Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial

Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer with poor prognosis. The current first-line treatment for advanced TNBC (aTNBC) is determined by the expression of programmed cell death-ligand 1 (PD-L1). In the ATRACTIB trial—a multicenter, single-arm, phase 2 stu...

Full description

Saved in:
Bibliographic Details
Main Authors: Gion, María (Author) , Blancas, Isabel (Author) , Cortez-Castedo, Patricia (Author) , Cortés-Salgado, Alfonso (Author) , Marmé, Frederik (Author) , Blanch, Salvador (Author) , Morales, Serafín (Author) , Díaz, Nieves (Author) , Calvo-Plaza, Isabel (Author) , Recalde, Sabela (Author) , Martínez-Bueno, Alejandro (Author) , Ruiz-Borrego, Manuel (Author) , Llabrés, Elisenda (Author) , Taberner, María Teresa (Author) , de Laurentiis, Michelino (Author) , García-Vicente, Silvia (Author) , Guerrero, José Antonio (Author) , Boix, Olga (Author) , Rodríguez-Morató, Jose (Author) , Sampayo-Cordero, Miguel (Author) , Antonarelli, Gabriele (Author) , Pérez-García, José Manuel (Author) , Cortés, Javier (Author) , Llombart-Cussac, Antonio (Author)
Format: Article (Journal)
Language:English
Published: August 2025
In: Nature medicine
Year: 2025, Volume: 31, Issue: 8, Pages: 2746-2754
ISSN:1546-170X
DOI:10.1038/s41591-025-03734-3
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41591-025-03734-3
Verlag, kostenfrei, Volltext: http://www.nature.com/articles/s41591-025-03734-3
Get full text
Author Notes:María Gion, Isabel Blancas, Patricia Cortez-Castedo, Alfonso Cortés-Salgado, Frederik Marmé, Salvador Blanch, Serafín Morales, Nieves Díaz, Isabel Calvo-Plaza, Sabela Recalde, Alejandro Martínez-Bueno, Manuel Ruiz-Borrego, Elisenda Llabrés, María Teresa Taberner, Michelino de Laurentiis, Silvia García-Vicente, José Antonio Guerrero, Olga Boix, Jose Rodríguez-Morató, Miguel Sampayo-Cordero, Gabriele Antonarelli, José Manuel Pérez-García, Javier Cortés, Antonio Llombart-Cussac & on behalf of ATRACTIB Trial Investigators
Description
Summary:Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer with poor prognosis. The current first-line treatment for advanced TNBC (aTNBC) is determined by the expression of programmed cell death-ligand 1 (PD-L1). In the ATRACTIB trial—a multicenter, single-arm, phase 2 study—we evaluated the combination of atezolizumab, paclitaxel and bevacizumab as first-line treatment for patients with aTNBC, independently of PD-L1 status. The primary endpoint was investigator-assessed progression-free survival. One hundred female patients were enrolled, with most evaluable tumors being PD-L1-negative (97.6%). The primary endpoint was met, with a median progression-free survival of 11.0 months (95% confidence interval (CI): 9.0-13.4; P < 0.001). The objective response rate was 63.0% (95% CI: 52.8-72.4) and median overall survival was 27.4 months (95% CI: 23.4-37.4). No treatment-related deaths or new safety signals were observed. This combination demonstrated significant antitumor activity as first-line therapy for aTNBC patients and merits further investigation. ClinicalTrials.gov Identifier: NCT04408118.
Item Description:Online veröffentlicht: 4. Juni 2025
Gesehen am 30.09.2025
Physical Description:Online Resource
ISSN:1546-170X
DOI:10.1038/s41591-025-03734-3

Similar Items